IL294621A - Tlr9 agonist oligonucleotides, compositions comprising same and uses thereof - Google Patents

Tlr9 agonist oligonucleotides, compositions comprising same and uses thereof

Info

Publication number
IL294621A
IL294621A IL294621A IL29462122A IL294621A IL 294621 A IL294621 A IL 294621A IL 294621 A IL294621 A IL 294621A IL 29462122 A IL29462122 A IL 29462122A IL 294621 A IL294621 A IL 294621A
Authority
IL
Israel
Prior art keywords
oligonucleotide
seq
pharmaceutical composition
disease
cells
Prior art date
Application number
IL294621A
Other languages
English (en)
Hebrew (he)
Original Assignee
Sbi Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sbi Biotech Co Ltd filed Critical Sbi Biotech Co Ltd
Publication of IL294621A publication Critical patent/IL294621A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL294621A 2020-01-10 2021-01-08 Tlr9 agonist oligonucleotides, compositions comprising same and uses thereof IL294621A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020002715 2020-01-10
PCT/JP2021/000543 WO2021141121A1 (en) 2020-01-10 2021-01-08 Novel tlr9 agonists

Publications (1)

Publication Number Publication Date
IL294621A true IL294621A (en) 2022-09-01

Family

ID=76787976

Family Applications (1)

Application Number Title Priority Date Filing Date
IL294621A IL294621A (en) 2020-01-10 2021-01-08 Tlr9 agonist oligonucleotides, compositions comprising same and uses thereof

Country Status (11)

Country Link
US (1) US20230323368A1 (OSRAM)
EP (1) EP4087931B1 (OSRAM)
JP (1) JP7750525B2 (OSRAM)
KR (1) KR20220125218A (OSRAM)
CN (1) CN114981436A (OSRAM)
AU (1) AU2021206355A1 (OSRAM)
BR (1) BR112022007935A2 (OSRAM)
CA (1) CA3161956A1 (OSRAM)
IL (1) IL294621A (OSRAM)
MX (1) MX2022005633A (OSRAM)
WO (1) WO2021141121A1 (OSRAM)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4313315A4 (en) * 2021-04-01 2025-02-19 TriSalus Life Sciences, Inc. CANCER THERAPY USING TOLL-LIKE RECEPTOR AGONISTS
CN117568339A (zh) * 2023-01-19 2024-02-20 华普生物技术(河北)股份有限公司 CpG寡核苷酸及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR040996A1 (es) * 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
MX2010001785A (es) * 2007-08-15 2010-03-10 Idera Pharmaceuticals Inc Moduladores de receptores tipo larga distancia.
WO2010018583A1 (en) * 2008-08-14 2010-02-18 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Toll-like receptor 9 agonists for the treatment of anxiety-related disorders and inflammatory disorders
AU2010229835B2 (en) * 2009-03-25 2015-01-15 The Board Of Regents Of The University Of Texas System Compositions for stimulation of mammalian innate immune resistance to pathogens
WO2014201516A2 (en) * 2013-06-20 2014-12-24 Immunexpress Pty Ltd Biomarker identification
EP3892284B1 (en) * 2015-05-29 2024-05-22 Merck Sharp & Dohme LLC Combination of a pd-1 antagonist and a cpg-c type oligonucleotide for treating cancer
CN109475612A (zh) * 2016-04-15 2019-03-15 戴纳瓦克斯技术公司 肿瘤内给予含有Toll样受体9激动剂和肿瘤抗原的颗粒用于治疗癌症
JP7145853B2 (ja) * 2016-11-09 2022-10-03 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 適応免疫調節のための方法および組成物

Also Published As

Publication number Publication date
US20230323368A1 (en) 2023-10-12
KR20220125218A (ko) 2022-09-14
JP2023510491A (ja) 2023-03-14
CA3161956A1 (en) 2021-07-15
BR112022007935A2 (pt) 2022-07-12
AU2021206355A1 (en) 2022-07-07
MX2022005633A (es) 2022-06-14
EP4087931B1 (en) 2024-12-25
CN114981436A (zh) 2022-08-30
JP7750525B2 (ja) 2025-10-07
EP4087931A1 (en) 2022-11-16
WO2021141121A1 (en) 2021-07-15
EP4087931A4 (en) 2024-01-24

Similar Documents

Publication Publication Date Title
Jeon et al. Toll-like receptor agonists as cancer vaccine adjuvants
Khong et al. Adjuvants for peptide-based cancer vaccines
AU2002359516B2 (en) Methods for treating cancer using a combination of a tumor-derived dendritic cell inhibitory factor antagonist and a toll-like receptor agonist
KR100829646B1 (ko) 치료상 유용한 합성 올리고뉴클레오타이드
JP6067893B2 (ja) 非コード免疫調節性共有結合閉鎖ｄｎａ構築物
JP2019515900A (ja) がんを処置するためのＴｏｌｌ様レセプター９アゴニストおよび腫瘍抗原を含む粒子の腫瘍内送達
ES2620748T3 (es) Nuevos agonistas del receptor de tipo toll 3 y procedimientos de su utilización
Yao et al. Immunotherapy for lung cancer combining the oligodeoxynucleotides of TLR9 agonist and TGF-β2 inhibitor
EP4087931B1 (en) Novel tlr9 agonists
Mizuno et al. Simultaneous delivery of doxorubicin and immunostimulatory CpG motif to tumors using a plasmid DNA/doxorubicin complex in mice
CN101161288B (zh) 寡核苷酸增强的肿瘤细胞裂解物及其在制备治疗肿瘤的药物中的应用
AU2014240165A1 (en) Methods and compositions for modulating regulatory T cell function
Sharma et al. Cytokines and chemokines are expressed at different levels in small and large murine colon-26 tumors following intratumoral injections of CpG ODN
RU2846775C1 (ru) Новые агонисты tlr9
Wang et al. Screening of novel immunostimulatory CpG ODNs and their anti-leukemic effects as immunoadjuvants of tumor vaccines in murine acute lymphoblastic leukemia
AU2024285571A1 (en) Armored t cells
AU2006200116B2 (en) Methods for treating cancer using a combination of a tumor-derived dendritic cell inhibitory factor antagonist and a toll-like receptor agonist
JP2020070252A (ja) 腫瘍免疫賦活剤
Lustgarten et al. Targeting Toll-Like Receptor for the Induction of Immune and Antitumor Responses
Meini Antitumor activity of locoregional combined CpG-ODN therapy in experimental carcinoma models